{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:25Z","timestamp":1790803585350,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-026-03923-2","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:26:04Z","timestamp":1772821564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of osimertinib combined with anti-VEGF therapy ramucirumab in managing leptomeningeal metastasis in EGFR-mutant NSCLC: a case report and literature review"],"prefix":"10.1186","volume":"21","author":[{"given":"Yueh-Hsun","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shiou","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Wang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"1","key":"3923_CR1","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","volume":"19","author":"H Cheng","year":"2018","unstructured":"Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19(1):e43\u201355.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3923_CR2","doi-asserted-by":"publisher","first-page":"22372","DOI":"10.1038\/s41598-022-26131-z","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Lin Z, Hong Y, Fu Y, Chen Y, Liu T, et al. Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer. Sci Rep. 2022;12(1):22372.","journal-title":"Sci Rep"},{"key":"3923_CR3","doi-asserted-by":"crossref","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018:Jco2018783118.","DOI":"10.1200\/JCO.2018.78.3118"},{"issue":"11","key":"3923_CR4","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","volume":"11","author":"YS Li","year":"2016","unstructured":"Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, et al. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations. J Thorac Oncol. 2016;11(11):1962\u20139.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3923_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","volume":"15","author":"MJ Ahn","year":"2020","unstructured":"Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, et al. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. J Thorac Oncol. 2020;15(4):637\u201348.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"3923_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, et al. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2020;38(6):538\u201347.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3923_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/1759-7714.13738","volume":"12","author":"ZQ Lu","year":"2021","unstructured":"Lu ZQ, Cai J, Wang X, Wei JP, Zeng ZM, Huang L, et al. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial. Thorac Cancer. 2021;12(2):172\u201380.","journal-title":"Thorac Cancer"},{"issue":"1","key":"3923_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-022-03331-9","volume":"20","author":"Y Yi","year":"2022","unstructured":"Yi Y, Cai J, Xu P, Xiong L, Lu Z, Zeng Z, et al. Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer. J Transl Med. 2022;20(1):122.","journal-title":"J Transl Med"},{"issue":"12","key":"3923_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655\u201369.","journal-title":"Lancet Oncol"},{"key":"3923_CR10","unstructured":"Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA et al. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Na\u00efve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol. 2024:Jco2400533."},{"issue":"7","key":"3923_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.23.02219","volume":"42","author":"PA J\u00e4nne","year":"2024","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2024;42(7):808\u201320.","journal-title":"J Clin Oncol"},{"issue":"16","key":"3923_CR12","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486\u201398.","journal-title":"N Engl J Med"},{"issue":"8","key":"3923_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"C Fan","year":"2021","unstructured":"Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, et al. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1\/2 Clinical Trial (Unique Identifier: ChiCTR1800016615). J Thorac Oncol. 2021;16(8):1359\u201368.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3923_CR14","doi-asserted-by":"publisher","first-page":"102384","DOI":"10.1016\/j.esmoop.2024.102384","volume":"9","author":"C Fan","year":"2024","unstructured":"Fan C, Jiang Z, Teng C, Song X, Li L, Shen W, et al. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial. ESMO Open. 2024;9(4):102384.","journal-title":"ESMO Open"},{"issue":"1","key":"3923_CR15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1186\/s12885-025-14337-z","volume":"25","author":"S Wu","year":"2025","unstructured":"Wu S, Qiu Z, Shi H, Yu W, Liu L, Wu L, et al. High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy. BMC Cancer. 2025;25(1):926.","journal-title":"BMC Cancer"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-03923-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-03923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-03923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T22:32:41Z","timestamp":1780007561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13019-026-03923-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3923"],"URL":"https:\/\/doi.org\/10.1186\/s13019-026-03923-2","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Tri-Service General Hospital Institutional Review Board (TSGHIRB) with the reference number TSGHIRB No.: A202415154. Written informed consent was obtained from the patients or their legal representatives for participation in the study and for the publication of their case details. The study was conducted in accordance with the Declaration of Helsinki and relevant institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the case details and associated images was obtained from the patients or their legal representatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}